<DOC>
	<DOCNO>NCT01611688</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial describe safety tolerability single intravenous ( i.v . ) subcutaneous ( s.c. ) dose NNC0215-0384 subject active rheumatoid arthritis ( RA ) background methotrexate ( MTX ) treatment .</brief_summary>
	<brief_title>First Human Dose Trial NNC0215-0384 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Active RA , characterise DAS28 ( CRP ) ( Disease Activity Score base 28 joint CRP ) 3.2 minimum two swollen joint base 68/66 joint count screen Concomitant treatment MTX ( 7.5 25 mg/week inclusive ) least 16 week , stable dose least 6 week prior dose Subjects chronic inflammatory autoimmune disease RA History current inflammatory joint disease RA gout ( crystal proven ) , psoriatic arthritis , juvenile idiopathic arthritis , current reactive arthritis Lyme disease Any active ongoing chronic infectious disease ( e.g . chronic osteomyelitis , chronic pyelonephritis ) require systemic antiinfectious treatment within 4 week prior randomisation Clinically significant cardiac cardiovascular disease Past current malignancy Latent active tuberculosis ( TB ) document : A positive QuantiFeronÂ® test ( test perform 2 month prior dose ) . One retest allow case inconclusive result . A history active TB within last 3 year even , treat effectively . A history active TB 3 year ago , documentation prior antiTB treatment appropriate duration type</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>